The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

October 22, 2012 11:51 ET

Medipattern Vascular Technology Matches Gold Standard in Blinded Study

Visualize:Vascular™ correlates to MRA

TORONTO, ONTARIO--(Marketwire - Oct. 22, 2012) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), congratulates authors Daniel Gurell, MD and Marc Prager, MD for their work comparing Visualize:Vascular™ to Magnetic Resonance Angiography (MRA). Their study shows that Visualize:Vascular's 3D luminal ultrasound visualization correlates well with MRA in a paper slated for presentation this coming weekend during the 2012 annual meeting of the Society of Radiologists in Ultrasound (SRU), which is a sub-committee of the American College of Radiology. The blinded study uses the results of ultrasound scans from 100 consecutive carotid arteries. Qualifying cases were further evaluated using MRA. Results were then compared between the two technologies. A correlation of 99%, p<.05 was found between the two imaging technologies. The results are statistically significant. Angiography is considered to be the gold standard in evaluating arterial integrity.

"Stroke is the leading cause of morbidity and the third leading cause of death. The first line of defense is the basic ultrasound Carotid Duplex Exam (CDE). Yet there are conditions when CDE is inhibited by artifacts, impacting results. Sensitivity and specificity of CDE results are statistically improved when used in conjunction with 3D Luminal Ultrasound Visualization (LUV), and may obviate the need for unnecessary additional testing allowing diseased patients to move more rapidly to definite therapy," commented Daniel Gurell, MD.

"We appreciate the effort of Dr. Gurell and Dr. Prager. Their efforts and enthusiasm for this technology made it a pleasure to work with their team. They provided a much needed opportunity to examine how our technology operated and differentiated itself in a real clinical setting. The experience has been vital to the development of our product," commented Jeff Collins, CEO of Medipattern. "Medipattern congratulates the doctors and their staff for creating an exacting head to head comparison of LUV and MRA. We appreciate all their efforts."

About UDMI:

University Diagnostic Medical Imaging ("UDMI") was founded in 1986, inspired by a vision of providing the best diagnostic imaging by experienced, board-certified radiologists. UDMI was the first full-service diagnostic radiology facility in the nation to earn all eight of the accreditations offered by the American College of Radiology. Today, UDMI is still owned and operated by radiologists who care about their patients and work collaboratively with doctors of many varied specialties to achieve the best outcome for all patients. Over the years, UDMI has built a reputation for excellence and professionalism. UDMI is committed to keeping abreast of the technological advances in radiology and to incorporating them into the practice. The physicians at UDMI intend to always be at the forefront of the medical field. For more information, please visit www.udmi.net.

About the Medipattern Corporation:

Medipattern® is an award-winning leader in the development and commercialization of healthcare solutions that positively impact people's lives through the prevention of disease and analysis of medical images and data. Medipattern's Knowledge-based Informatics (MKI) platform enables delivery of these streamlined solutions. Medipattern mHealth uses patented prevention technologies to engage, coach and monitor people in achieving their personalized goals. Medipattern iaHealth uses patented pattern recognition technology to analyze medical data to aid medical practitioners in the assessment of disease and critical anatomy. For more information, please visit the Company's website: www.medipattern.com.

Medipattern® is registered trademarks of The Medipattern Corporation. Visualize:Vascular™ is a registered trademark of Medipattern.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). These factors should be considered carefully, and readers should not place undue reliance on Medipattern's forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information